Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma”

10 trials

Showing 10 of 10 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07128693
What this trial is testing

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 60
Large-scale testing (Phase 3)Study completedNCT03783442
What this trial is testing

Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma (ESCC)
BeiGene 649
Testing effectiveness (Phase 2)Study completedNCT04732494
What this trial is testing

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
BeiGene 125
Large-scale testing (Phase 3)Study completedNCT03748134
What this trial is testing

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Who this might be right for
Esophageal Squamous Cell Carcinoma
Innovent Biologics (Suzhou) Co. Ltd. 746
Large-scale testing (Phase 3)Study completedNCT04187352
What this trial is testing

CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Who this might be right for
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
CStone Pharmaceuticals 540
Large-scale testing (Phase 3)Looking for participantsNCT04415853
What this trial is testing

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Who this might be right for
Esophageal Cancer
Sunshine Lake Pharma Co., Ltd. 416
Testing effectiveness (Phase 2)Study completedNCT00021047
What this trial is testing

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Who this might be right for
Esophageal CancerExtrahepatic Bile Duct CancerGastric Cancer+3 more
National Institutes of Health Clinical Center (CC)
Large-scale testing (Phase 3)Study completedNCT04540211
What this trial is testing

Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Who this might be right for
Esophageal Cancer
Hoffmann-La Roche 461
Early research (Phase 1)Study completedNCT00010023
What this trial is testing

Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Cancer
NYU Langone Health
Early research (Phase 1)Study completedNCT04641871
What this trial is testing

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

Who this might be right for
Metastatic CancerSolid Tumor
Symphogen A/S 78

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation